Skip to main content
SpringerLink
Log in

Contraception in Rheumatic Disease Patients

  • Chapter
  • First Online:
Contraception and Pregnancy in Patients with Rheumatic Disease

  • 758 Accesses

Abstract

Safe and effective contraception is widely available to women with rheumatic diseases, although consistent contraception, even in patients on potentially teratogenic medications, continues to be underutilized. The most effective contraceptives are the long-acting forms, including intrauterine devices (IUDs), subdermal implants, and depot medroxyprogesterone acetate injections. Other effective methods include combined hormonal contraceptives. Barrier methods are the least effective, although they offer some protection against sexually transmitted diseases. The optimal choice of contraceptive for a particular patient depends on rheumatic disease diagnosis, level of disease activity, autoantibody profile, medications, physical limitations, and personal preference. Estrogen-containing contraceptives are a particular concern: they should be avoided in patients with antiphospholipid antibodies and active lupus erythematosus or other prothrombotic conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol. 1993;32(3):227–30.

    PubMed  CAS  Google Scholar 

  2. Schwartz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008;59(6):863–6.

    Google Scholar 

  3. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, Schwartz EB. Contraceptive counseling and use among women with systemic lupus: a gap in health care quality? Arthritis Care Res. 2011;63(3):358–65.

    Google Scholar 

  4. Østensen M, Von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol. 2007;34(6):1266–9.

    PubMed  Google Scholar 

  5. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States 2006–2010, and changes in patterns of use since 1995. National Health Statistics Reports 2012: no. 60, 18 October, 2012.

    Google Scholar 

  6. Britto MT, Rosenthal SL, Taylor J, Passo MH. Improving rheumatologist’ screening for alcohol and sexual activity. Arch Pediatr Adolesc Med. 2000;154(5):478–83.

    PubMed  CAS  Google Scholar 

  7. Mohammad A, Kilcoyne A, Bond U, Regan M, Phelan M. Methotrexate information booklet study 2008. Clin Exp Rheumatol. 2009;27(4):649–50.

    PubMed  CAS  Google Scholar 

  8. Yazdany J, Panopalis P, Gillis J, Schmajuk G, MacLean C, Wofsy D, et al. A quality indicator set for systemic lupus erythematosus. Arthritis Care Res. 2009;61(3):370–7.

    Google Scholar 

  9. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm318880.htm

  10. https://www.mycophenolaterems.com/

  11. Amy JJ, Tripathi V. Contraception for women: an evidence based overview. BMJ. 2009;339(7):b2895.

    PubMed  Google Scholar 

  12. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010, adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th ed. Morbidity and Mortality Weekly Report: 18 June 2010/59(RR04);1–6.

    Google Scholar 

  13. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth J, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998–2007.

    PubMed  CAS  Google Scholar 

  14. Jensen JT, Mishell Jr DR. Family planning: contraception, sterilization and pregnancy termination. In: Lentz GM, Lobo RA, Gershenson DM, Katz VL, editors. Comprehensive gynecology. Philadelphia: Elsevier Mosby; 2012. p. 215–75.

    Google Scholar 

  15. Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plann Perspect. 1991;23:226–7.

    PubMed  CAS  Google Scholar 

  16. D’Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007;75(6):S2–7.

    PubMed  Google Scholar 

  17. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–32.

    PubMed  CAS  Google Scholar 

  18. Lyus R, Lohr P, Prager S. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception. 2010;81(5):367–71.

    PubMed  CAS  Google Scholar 

  19. Farley T, Rowe P, Meirik O, Rosenberg M, Chen H. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–8.

    PubMed  CAS  Google Scholar 

  20. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine device versus hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197(2):144-e1–e8.

    Google Scholar 

  21. Browne H, Manipalviratn S, Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol. 2008;112(3):667–9.

    PubMed  PubMed Central  Google Scholar 

  22. Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26(2):99–102.

    PubMed  CAS  Google Scholar 

  23. Nelson A. Contraindications to IUD and IUS use. Contraception. 2007;75(6):S76–81.

    PubMed  Google Scholar 

  24. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2):339–46.

    PubMed  Google Scholar 

  25. Jick SS, Hagberg KW, Kaye JA. “Ortho Evra” and venous thromboembolism: an update. Contraception. 2010;81:452–3.

    PubMed  Google Scholar 

  26. Dore DD, Normal H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81:408–13.

    PubMed  CAS  Google Scholar 

  27. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190:S5–22.

    PubMed  CAS  Google Scholar 

  28. Mansour D. Experience with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care. 2002;7:35–41.

    PubMed  CAS  Google Scholar 

  29. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793–7.

    PubMed  CAS  Google Scholar 

  30. Moreno V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papilloma virus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085–92.

    PubMed  CAS  Google Scholar 

  31. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.

    Google Scholar 

  32. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395–403.

    PubMed  CAS  Google Scholar 

  33. White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception. 2006;74(4):293–6.

    PubMed  CAS  Google Scholar 

  34. Van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thromboembolic risk of oral contraceptives, effects of oestrogen dose and progestin type: results of the MEGA case-control study. BMJ. 2009;339:b2921.

    Google Scholar 

  35. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction of coagulation factor levels and oral contraceptives. Thromb Haemost. 2003;89:493–8.

    PubMed  CAS  Google Scholar 

  36. Tanis BC, Rosendaal FR. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med. 2003;3(1):69–84. Thieme Medical Publishers.

    Google Scholar 

  37. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FL, van der Graf Y, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–8.

    PubMed  Google Scholar 

  38. Pettiti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low dose contraceptives. N Engl J Med. 1996;335:8–15.

    Google Scholar 

  39. Martinelli I, Battaglioli T, Mannucci PM. Pharmacologic aspects of the use of oral contraceptives and the risk of thrombosis. Pharmacogenet Genomics. 2003;3:589–94.

    Google Scholar 

  40. Lidegaard Ø, Løkkegaard E, Jensen A, Scovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.

    PubMed  CAS  Google Scholar 

  41. Lewis MA, Heinnemann LAJ, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the transnational study on oral contraceptives and the health of young women. Contraception. 1997;56:129.

    PubMed  CAS  Google Scholar 

  42. Van den Bosch MAAJ, Kemmeren JM, Tanis BC, Mali WP, Helmerhorst FM, Rosendaal FR, et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost. 2003;1:439–44.

    Google Scholar 

  43. Biswas J, Mann M, Webberley H. Oral contraception. Obstet Gynaecol Reprod Med. 2008;18(12):317–23.

    Google Scholar 

  44. Haider Z, D’Souza R. Non-contraceptive benefits and risks of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):249–62.

    PubMed  Google Scholar 

  45. Hubacher D, Lopez L, Steiner MJ, Dorfinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: a systematic review and evidence based comparisons. Contraception. 2009;80:113–8.

    PubMed  CAS  Google Scholar 

  46. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Comm Opinion number 415: Depo- Medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;12:727–30.

    Google Scholar 

  47. ACOG Committee on Practice Bulletins – Gynecology. ACOG Practice Bulletin number 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–72.

    Google Scholar 

  48. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contracpetives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception. 2001;64:125.

    PubMed  CAS  Google Scholar 

  49. Cardiovascular disease and use of oral and injectable progesterone-only contraceptives and combined injectable contraceptives. Results of an international multicenter case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998;57(5):315–24.

    Google Scholar 

  50. Grossman D. Moving oral contraceptives over-the-counter as a strategy to reduce unintended pregnancy. Ann Intern Med. 2013;158:839–40. doi:10.7326/0003-4819-158-11-201306040-00629 (Published online 26 March 2013).

    PubMed  Google Scholar 

  51. Westley E. Emergency contraception: a global overview. J Am Med Womens Assoc. 1998;53(5 Suppl 2):215.

    PubMed  CAS  Google Scholar 

  52. Steinberg AD, Melez KA, Raveche ES. Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum. 1979;22:1170–6.

    PubMed  CAS  Google Scholar 

  53. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 1979;22:1195–8.

    PubMed  CAS  Google Scholar 

  54. Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P, Bach JF. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. 1982;25(6):618–23.

    PubMed  CAS  Google Scholar 

  55. Ansar Ahmend S, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol. 1985;121:531–51.

    Google Scholar 

  56. Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1997;40:804–8.

    PubMed  CAS  Google Scholar 

  57. Bernier MO, Mikaeloff Y, Hudson M, Suiss AS. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Care Res. 2009;61(4):476–81.

    CAS  Google Scholar 

  58. Cooper GS, Dooley MA, Treadwell EL, St. Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population based, case-control study. Arthritis Rheum. 2002;46:1830–9.

    PubMed  CAS  Google Scholar 

  59. Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G. Risk factors for developing systemic lupus erythematosus: a case-control study in Southern Sweden. Rheumatology. 2002;41:563–71.

    PubMed  CAS  Google Scholar 

  60. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn B, Sammaritano L, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353: 2550–8.

    PubMed  CAS  Google Scholar 

  61. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539–49.

    PubMed  CAS  Google Scholar 

  62. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114(2):341–53.

    PubMed  Google Scholar 

  63. Shortridge E, Miller K. Contraindications to oral contraceptive use among women in the United States 1999–2001. Contraception. 2007;75:355–60.

    PubMed  Google Scholar 

  64. Chabbert-Buffet N, Amoura Z, Scarabin PY, Frances C, Levy DP, Galicier L, et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception. 2011;83(3):229–37.

    PubMed  CAS  Google Scholar 

  65. Danowski A, de Azevedo MNL, Petrie M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195–9.

    PubMed  CAS  Google Scholar 

  66. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis Rheum. 2007;56(7):2382–91.

    PubMed  CAS  Google Scholar 

  67. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15.

    PubMed  PubMed Central  Google Scholar 

  68. Bloemenkamp KWM, Rosendaal FR, Helmerhorst F, Vandenbrouke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49–52.

    PubMed  CAS  Google Scholar 

  69. World Health Organization. Reproductive Health. Medical eligibility criteria for contraceptive use. Geneva: World Health Organization; 2010.

    Google Scholar 

  70. Forastiero R, Martinuzzo M, Adamczuk Y, Varela ML, Pombo G, Carreras LO. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica. 2001;86(7):735–41.

    PubMed  CAS  Google Scholar 

  71. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104:143–8.

    PubMed  CAS  Google Scholar 

  72. Asherson RA, Harris EN, Hughes GRV, Farquaharson RG. Complications of oral contraceptives and aPL: reply to the letter by Bruneau et al. Arthritis Rheum. 1988;31:575.

    PubMed  CAS  Google Scholar 

  73. Millan-Mon A, Porto JL, Novo C, Garcia-Martin C, Guitan D. Hepatic infarction in a pregnant patient with ‘primary’ antiphospholipid syndrome. Lupus. 1993;2:275–9.

    PubMed  CAS  Google Scholar 

  74. Asherson RA, Buchanan N, Baguley E, Hughes GR. Postpartum bilateral renal vein thrombosis in the primary antiphospholipid syndrome. J Rheumatol. 1993;20(5):874.

    PubMed  CAS  Google Scholar 

  75. Bacci S, Urquiola G, del Medico P, Sanabria JA, Bacci JC, Guzman M, et al. Budd-Chiari syndrome, pulmonary thromboembolism, and deep venous thrombosis associated with the “lupus anticoagulant” and recent use of oral contraceptives. G E N. 1990;44(3):237.

    PubMed  CAS  Google Scholar 

  76. Girolami A, Zanon E, Zanardi S, Saracino MA, Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 1996;7:497–501.

    PubMed  CAS  Google Scholar 

  77. Asherson RA, Harris NE, Gharavi AE, Hughes GRV. Systemic lupus erythematosus, antiphospholipid antibodies, chorea and oral contraceptives. Arthritis Rheum. 1986;29: 1535–6.

    PubMed  CAS  Google Scholar 

  78. Islander MK, Khan M. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus. J Rheumatol. 1989;16:850.

    Google Scholar 

  79. Vad S, Lakos G, Kiss E, Sipka S, Csorba R, Poka R. Antiphospholipid antibodies in young women with and without oral contraceptive use. Blood Coagul Fibrinolysis. 2003;14(1):57–60.

    PubMed  CAS  Google Scholar 

  80. Cretel E, Cacoub P, Le Thi Huong D, Gompel A, Amoura Z, Piette JC. Massive ovarian hemorrhage complicating oral anticoagulation in the antiphospholipid syndrome: a report of three cases. Lupus. 1999;8:482–5.

    PubMed  CAS  Google Scholar 

  81. Yamakami LYS, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20:523–6.

    PubMed  CAS  Google Scholar 

  82. Østensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol. 1983;12(2):69–72.

    PubMed  Google Scholar 

  83. Moskowitz MA, Jick SS, Burnside S, Wallis WJ, Disckson JF, Hunter JR, et al. The relationship of oral contraceptive use to rheumatoid arthritis. Epidemiology. 1990;1(2):153–6.

    PubMed  CAS  Google Scholar 

  84. Anonymous. Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Royal College of General Practitioners’ Oral Contraception Study. Lancet 1978;1(8064):569–71.

    Google Scholar 

  85. Doran MF, Crowson CS, O’Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol. 2004;31:207–13.

    PubMed  CAS  Google Scholar 

  86. Brennan P, Bankhead C, Silman A, Symmons D. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum. 1997;26(6):817–23 (current use protective).

    PubMed  CAS  Google Scholar 

  87. Hazes JM, Dijkmans BC, Vanddenbroucke JP, de Vries RR, Cats A. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum. 1990;33(2):173–9.

    PubMed  CAS  Google Scholar 

  88. Spector TM, Roman E, Silman A. The pill, parity and rheumatoid arthritis. Arthritis Rheum. 1990;33(6):782–9.

    PubMed  CAS  Google Scholar 

  89. Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis. 1996;55(2):94–8 (OCP protective effect on risk of severe RA).

    PubMed  CAS  PubMed Central  Google Scholar 

  90. Pikwer M, Bergström U, Nilsson JÅ, Jacobsson L, Berglund G, Turesson C. Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):526–30.

    PubMed  CAS  Google Scholar 

  91. Vessey MP, Villard-Mackintosh L, Yeates D. Oral contraceptives, cigarette smoking, and other factor factors in relation to arthritis. Contraception. 1987;35(5):457–64.

    PubMed  CAS  Google Scholar 

  92. Drossaers-Bakker KW, Zwinderman AH, Van Zeben D, Breedveld FC, Hazes JMW. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002;61(5):405–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  93. Hernandez-Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, et al. Exogenous sex hormones and the risk of rheumatoid arthritis. Arthritis Rheum. 1990;33(7):947–53.

    PubMed  CAS  Google Scholar 

  94. Farr SL, Folger SG, Paulsen ME, Curtis KM. Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. Contraception. 2010;82(1):64–71.

    PubMed  Google Scholar 

  95. Hall GM, Daniels M, Huskisson EC, Spector TD. A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis. 1994;53(2):112–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  96. Van der Brink HR, van Everdingen AA, van Wijk MJ, Jacobs JW, Bijilsma JW. Adjuvant oestrogen therapy does not improve disease activity in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis. 1993;52(12):862–5.

    PubMed  PubMed Central  Google Scholar 

  97. Masi AT, Feigenbaum SL, Chatterton RT, Cutolo M. Integrated hormonal–immunological–vascular systems interactions in the rheumatic diseases. Clin Exp Rheumatol. 1995;13(2):203.

    PubMed  CAS  Google Scholar 

  98. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci. 2002;966(1):131–42.

    PubMed  CAS  Google Scholar 

  99. Margolis HM, Caplan PS. The effect of some steroids (testosterone prionate, desoxycorticosterone acetate and ascorbic acid, and 21-acetoxy-5-pregnenolone artisone acetate) in rheumatoid arthritis. Ann Intern Med. 1951;34:61.

    PubMed  CAS  Google Scholar 

  100. Bird HA, Burkinshaw L, Pearson D, Atkinson PJ, Leatham PA, Hill J, et al. A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women. Ann Rheum Dis. 1987;46(3):237–43.

    PubMed  CAS  PubMed Central  Google Scholar 

  101. Booij A, Biewenga-Booij CM, Huber-Brunning O, Cornelis C, Jacobs JW, Bijlsma JW. Androgens as adjuvant treatment in postmenopausal patients with rheumatoid arthritis. Ann Rheum Dis. 1996;55:811–5.

    CAS  Google Scholar 

  102. Lekakis J, Mavrikaks M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J. 1998;136(5):905–12.

    PubMed  CAS  Google Scholar 

  103. Lekakis J, Mavrikakis M, Emmanuel M, Prassopoulos V, Papmichael C, Moulopoulou D, et al. Acute estrogen administration can reverse cold-induced coronary Raynaud’s phenomenon in systemic sclerosis. Clin Exp Rheumatol. 1996;14(4):421–4.

    PubMed  CAS  Google Scholar 

  104. Bartelink ML, Wollerheim H, van de Lisdonk E, Thien T. Raynaud’s phenomenon: subjective influence of female sex hormones. Int Angiol. 1992;11:309–15.

    PubMed  CAS  Google Scholar 

  105. Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol. 2006;35(6):468–71.

    PubMed  CAS  Google Scholar 

  106. Tiidus PM. Influence of estrogen on skeletal muscle damage, inflammation, and repair. Exerc Sport Sci Rev. 2003;31(1):40–4.

    PubMed  Google Scholar 

  107. Serada D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol. 2006;142(1):70–2.

    Google Scholar 

  108. Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol. 1990;163:2153–9.

    PubMed  CAS  Google Scholar 

  109. Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy. J Hum Pharmacol Drug Ther. 1997;17(6):1178–97.

    CAS  Google Scholar 

  110. Dickinson BD, Altman R, Nielsen N, Sterling ML. For the Council on Scientific Affairs, American Medical Association. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98(5):853–60.

    PubMed  CAS  Google Scholar 

  111. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adegboyega Q, et al. The interaction between St. John’s wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74:525–35.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, 535 East 70th Street, New York, NY, 10021, USA

    Lisa R. Sammaritano M.D.

Authors
  1. Lisa R. Sammaritano M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa R. Sammaritano M.D. .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, New York, USA

    Lisa R. Sammaritano

  2. Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Bonnie L. Bermas

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sammaritano, L.R. (2014). Contraception in Rheumatic Disease Patients. In: Sammaritano, L., Bermas, B. (eds) Contraception and Pregnancy in Patients with Rheumatic Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0673-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0673-4_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0672-7

  • Online ISBN: 978-1-4939-0673-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation